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Raffaele Pisana IRCCS, Rome, Italy AQ1By contrast with other southern European people, north
Portuguese population registers an especially high
prevalence of hypertension and stroke incidence. We
designed a cohort study to identify individuals presenting
accelerated and premature arterial aging in the Portuguese
population. Pulse wave velocity (PWV) was measured in
randomly sampled population dwellers aged 18–96 years
from northern Portugal, and used as a marker of early
vascular aging (EVA). Of the 3038 individuals enrolled,
2542 completed the evaluation. Mean PWV value for the
entire population was 8.4m/s (men: 8.6m/s; women:
8.2m/s; P< 0.02). The individuals were classified with EVA
if their PWV was at least 97.5th percentile of z-score for
mean PWV values adjusted for age (using normal
European reference values as comparators). The overall
prevalence of EVA was 12.5%; 26.1% of individuals below
30 years presented this feature and 40.2% of individuals
in that same age strata were placed above the 90th
percentile of PWV; and 18.7% of the population exhibited
PWV values above 10m/s, with male predominance
(17.2% of men aged 40–49 years had PWV>10m/s).
Logistic regression models indicated gender differences
concerning the risk of developing large artery damage,
with women having the same odds of PWV above 10m/s
10 years later than men.
Conclusion: The population PWV values were higher than
expected in a low cardiovascular risk area (Portugal). High
prevalence rates of EVA and noteworthy large artery
damage in young ages were found.
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hanges in arterial wall structure are part of the aging
process and occur as a result of mechanical, bio-
chemical, or metabolic insults. These changes are
attenuated by local repair mechanisms [1]. Arterial stiffness
progresses with age and can be accelerated by differentJournal of Hypertensionfactors, high blood pressure (BP) being one of the most
relevant [2]. The impact of these factors on arterial stiffness
is significant in younger and older individuals as well as in
men and women, and across different countries [3,4]. Other
contributors to this unsuccessful aging process can be
related to early-life determinants (fetal programming, intra-
uterine growth retardation, low birth weight, postnatal
growth pattern) [5] and genetic determinants, concerning
different aspects of arterial stiffness heritability that range
from arterial wall composition to transcriptional pathways
related to gene expression [6–9].
Early vascular aging (EVA) is a concept with growing
interest and relevance [1,5,10–14]. It corresponds to unsuc-
cessful aging: the normal aging process is accelerated and
arteries display characteristics typically observed at older
(chronological) ages. The early identification of individuals
at increased absolute [15] and relative cardiovascular risk
when compared with individuals with the same age is
critical; measurement of arterial stiffness through pulse
wave velocity (PWV) fulfills part of this issue [16]. This
group of individuals would benefit from clinical interven-
tion to reduce risk through cardiovascular risk factor
(CVRF) control [17] and healthy lifestyle behaviors: exercise
[18], diet [19], and lower salt consumption [20]. This is called
the aggressive decrease of atherosclerosis modifiers
strategy [11].
Arterial stiffness measurement is particularly useful to
obtain a comprehensive insight of the accumulated effect of
different CVRF through an extended time window, in thewww.jhypertension.com 1
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Cunha et al.vascular aging process [11]. Longitudinal follow-up of
this measurement could also identify those whose clinical
intervention has failed to achieve CVRF control and
regression/stabilization of early arterial stiffness signs
[21]. Carotid–femoral (c-f)PWV reference values adjusted
to age, sex, and influencing CVRF have been recently
published [16], allowing the clinician to compare an indi-
vidual’s measure of arterial damage against the expected
value for that same age.
By contrast with other southern European people, north-
ern Portuguese population registers an especially high
stroke incidence [22]. Previous reports published on this
population have related increased arterial stiffness to salt
intake and prevalence of hypertension (HTN); however, no
study was designed to assess EVA patterns. Assessment of
arterial wall damage as a marker of increased risk to the
development of cardiovascular disease (CVD), cardiovas-
cular events, and all-cause mortality [15,23] is therefore of
particular interest, in this geographic area.
We designed a large-scale population-based cohort
study to accurately establish the prevalence of several CVRF
and determine the distribution of PWV values and signs of
pathological arterial stiffness. The aim was to identify
individuals presenting accelerated and premature arterial
aging, through age-adjusted analysis, or those who have
PWV values above the 10m/s threshold [24].
PATIENTS ANDMETHODS
The methodology employed in this study has already been
detailed elsewhere [25,26]. Briefly, a representative sample
of the population from two adjacent cities (Guimara˜es and
Vizela) was randomly selected and evaluated on two differ-
ent occasions at least 3 months apart, after signing a written
consent form approved by an Ethics Committee. In Portu-
gal, every citizen must be registered in the Primary Com-
munity Healthcare Centre (PCHCC) of his/her residence
area. Comparing the characteristics of citizens living in
Guimara˜es/Vizela (Statistics Portugal for the year 2006)
and the same information of those with an actual registry
in one of the PCHCC facilities operating in the two cities, the
difference between both the lists was inferior to 2%, there-
fore allowing the consideration that, for practical use, the
populations enrolled in PCHCC and living in Guimara˜es/
Vizela are virtually the same. Therefore, participants have
been randomly selected from the list of citizens currently
living in Guimara˜es and Vizela.
Considering that there was no available estimate of the
prevalence of EVA or large artery damage for the Portuguese
population, the sample selection was based considering the
estimated prevalence of HTN in Portugal. A sample size of at
least 2339 participants was required to achieve 2% precision
in an estimated prevalence of HTN of 41.2%. Thus, a sample
of the adult population (>18 years of age) stratified by age
was defined previewing the necessity of including 4000
individuals (95% confidence intervalwith an estimation error
inferior to 2%, considering a 25% safety margin to cope with
nonadherence and dropout rate between visits).
Anticipating a higher nonadherence and dropout rates
on younger and professionally active individuals, the num-
ber of randomized individuals to enroll was stratified2 www.jhypertension.comunevenly according to their age (2000 individuals would
be <35 years of age, 1000 individuals would have 35–65
years of age, and 1000 individuals would be >65 years).
The estimation of PWV values for the population was
adjusted by age and sex agreeing to the known distribution
of these characteristics in the population of the two cities,
according to Statistics Portugal for the year 2006.
The lists of randomized individuals were delivered to the
corresponding family doctors so that they could contact and
enroll them, and obtain the written consent to participate. It
was therefore clear that only randomly assigned individuals
could be enrolled and that no volunteers or physician-
selected individuals would be included. If the individual
refused, the general practitioner could not replace him/her
with a volunteer or with someone from his/her practice.
Only randomized individuals were accepted.
Individuals were observed in the morning, fasting over-
night, and carrying their usual drug prescriptions. No intake
of caffeinated beverages or tobacco use was allowed. The
participants underwent a standardized workup including
medical history, and biologic and arterial measurements.
Trained physicians performed BP measurements at every
occasion; training sessions performed prior to the begin-
ning of the study insured standardization of BP and PWV
measurements. BP was measured three times (at each visit)
with participants in a sitting position, after a 15-min resting
period, taken with 2min interval, using the validated
OMRON-705IT device. During their first visit, patients were
then placed in the supine position and c-fPWV was
measured using the Sphygmocor device.
Measured PWV values were standardized and normal-
ized to allow us to compare the obtained values with the
ones published as European reference [16] (details in
Supplemental Material, http://links.lww.com/HJH/A474).
Definition of early vascular aging
The primary definition of EVA was based upon the age-
adjusted normal population of the European reference val-
ues collaboration (ERVC) [16]. Accordingly, EVAwas defined
as a PWV of at least 97.5th percentile of z-score for mean
PWV values adjusted for age, using the normal population
PWV values as comparator. The normal population in the
ERVC included the so-called normotensive ‘healthy’ individ-
uals, as they did not have any known CVRF or CVD and
presented optimal or normal BP [16]. In a separate exercise,
we also tested another definition of EVA wherein we
included individuals with PWV values 2 standard deviation
(SD) above themean PWVvalue determined as reference for
someone with his/her age and BP class; as comparator, we
used the reference population values also presented by the
ERVC [16] – the total reference population in that collabor-
ation included individuals with high–normal to Grade 3 BP
(untreated), dyslipidemia (untreated), smokers, and no dia-
betes or established CVD [16].
We also considered the existence of arterial target organ
damage by dichotomizing PWV values above 10m/s or
below [24].
Statistical analysis
Statistical methodology concerning population sampling,
database elaboration, and management, as well asVolume 33  Number 1  Month 2015
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TABLE 1. Clinical characteristics of 2542 individuals studied
Total
Number of cases/female % 2542 / 55
Mean age (years) 45.5
Mean BMI (kg/m2) (SD) 26.6 (4.6)
Mean SBP/DBP (mmHg) 129.8/76.8
Hypertension (%) 31.6
Diabetes (%) 9.1
Dyslipidemia (%) 75.1
Years of education: 4/5–9/10–12/>12 (%) 53.7/22.3/15.7/7.8
Current/former/no smoker (%) 18.8/16.1/65.1
Antihypertensive treatment (%) 22.0
Antidiabetic treatment (%) 6.7
Use of lipid-lowering drugs (%) 17.7
Established cardiovascular disease (%) 5.0
PWV mean values (m/s) Total Male Female
<30 years (249/311) 7.1 7.3 6.8
30–39 years (236/334) 7.7 7.9 7.4
40–49 years (122/154) 8.3 8.5 8.1
50–59 years (136/160) 8.5 8.6 8.5
60–69 years (141/169) 9.9 10.3 9.5
70–79 years (145/157) 10.8 11.6 10.2
80 years (22/25) 11.4 12.1 11.0
All (1051/1310) 8.4 8.6 8.2
Numbers in brackets correspond AQ8to the number of male (M) and female (F) individuals
(M/F) in each age class. PWV, pulse wave velocity; SD, standard deviation.
From arterial stiffness to early vascular agingpredefined statistical analysis have already been addressed
elsewhere [25]. Prevalence of different studied character-
istics was estimated and calculated by demographic
characteristics (age group, sex, education level) and
risk factors. Linear regression models were studied with
PWV as the dependent variable and with independent
variables that included age, age2, sex, SBP (mean of
four measurements), heart rate (HR), BMI, years of edu-
cation, tobacco use, family history of premature CVD,
antihypertensive medication use, fasting glucose, lipid pro-
file, mean estimated glomerular filtration rate, C-reactive
protein, antidiabetic treatment, antilipidic treatment, and
known CVD.
To avoid collinearity problems, age and SBP were stand-
ardized by their mean and SD. Logarithmic transformation
of PWV values was performed to guarantee a normal
homocedastic distribution. Because of detected interactions
between sex and major risk factor, we created separate
models for men and women. Logistic regression models
were constructed to study contributing variables to both the
development of large artery damage (PWV > 10m/s) and
EVA. Again, as men and women presented a different
discriminative value of age for large artery damage, two
different models, based on gender, are presented (Figure
SM1 and Supplemental Material, http://links.lww.com/
HJH/A474).
RESULTS
From the initial 4000 randomized individuals, 962 could not
participate (these individuals either refused to participate,
were no longer residents, or were either pregnant or bed-
ridden). From the 3038 enrolled, the dropout rate was
16.1%, between the two clinical observations defined in
the study [25,26]. The individuals who dropped out of the
study were similar in terms of age, sex, and years of
education when compared with the adherent individuals
[26].
The distribution of population by age class and sex, their
clinical characteristics, and mean values of PWV distri-
bution stratified and adjusted for age/sex are summarized
in Table 1. In Table 2, we present the prevalence of relevant
biologic characteristics (CVRFs, CVD, pharmacologic treat-
ments used), stratified by age class. The adjusted mean
PWV value for the entire population was 8.4m/s (8.2m/s
for women; 8.6m/s for men). Men had an average 0.6m/s
higher PWV than women (P< 0.001). The sex difference in
PWV values was observable in any age class (P< 0.02) and
it increased with advancing age: from 0.4m/s in individuals
below 30 years to 1.3m/s in individuals of at least 70 years.
Regression analysis showed that in males, the increase in
PWV depended quadratically on age. In females, a linear
model best described this association and in addition to age,
SBP and HR were significantly associated with PWV
(R2¼ 0.44). In males, in addition to age and age2, SBP,
HR, and fasting glucose were also significant variables
associated with PWV (R2¼ 0.49). Stepwise regression
showed that the main associations, by order of importance,
were with age, SBP, and HR. The observed differences
between genders justify the adoption of gender-specific
regression models Table 3.Journal of HypertensionEarly vascular aging
Using the above-mentioned z-scores methodology, every
individual was ranked within his/her age strata. We present
the percentage of individuals placed above the 90th, 95th,
and 97.5th percentile of predicted PWV for their age class in
Fig. 1.
EVA was recorded in 12.5% of the total population.
Strikingly, 19.3% of individuals below 40 years and 26.1%
of individuals below 30 would be classified as EVA indi-
viduals, that is, one out of every four young adults. In
Supplemental Material, http://links.lww.com/HJH/A474,
the calculation of EVA prevalence using the 2SD above
the mean PWV value adjusted for age and BP class is
presented (using the European ‘reference’ population val-
ues) – Figure SM2, http://links.lww.com/HJH/A474. With
this alternative method of calculation, observations of the
same nature can be made regarding the high prevalence of
EVA, notably at ages below 50 years. With any of the
methods applied, there was a significantly higher preva-
lence of EVA individuals of the male gender in age classes
below 40 years.
In Table SM3, http://links.lww.com/HJH/A474, we
present the biologic characteristics of individuals below
50 years of age classified as having EVA, by comparison
with those classified as normal arterial aging within the
same age strata. The EVA individuals presented higher male
prevalence, mean BP, HTN prevalence, and a slight
increase in mean HR, but lower high-density lipoprotein
cholesterol levels. In Table SM4, http://links.lww.com/
HJH/A474, we show the results of the logistic regression
analysis of EVA. Identified variables were age below
30 years [odds ratio (OR)¼ 3.2], male sex (OR¼ 1.4), BP
above or equal to the high–normal category (ORoptimalwww.jhypertension.com 3
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TABLE 2. Prevalence (percent) of relevant biological characteristics stratified by age group (crude rates)
Age
(years)
Current
smokers
Former
smokers Diabetes Dyslipidemia HTN CKD CVD
HTN
treatment
Diabetes
treatment
Lipid
treatment
<30 30.2 7.8 0.4 49.5 2.7 0.4 0.2 0.7 0.2 0.7
30–39 25.9 9.7 1.2 68.1 10.8 0.7 0.5 3.6 0.5 1.9
40–49 26.6 19.6 6.6 81.8 25.2 1.4 1.7 12.6 4.9 8.4
50–59 13.8 21.1 14.8 88.5 44.7 1.7 7.9 31.9 11.2 31.3
60–69 8.7 20.9 25.1 91.3 71.7 4.4 9.0 53.2 20.2 43.1
70 2.4 25.1 23.3 90.8 79.9 13.7 21.2 60.9 14.1 44.4
CKD, chronic kidney disease; CVD, cardiovascular disease (including ischemic stroke, hemorrhagic stroke, acute coronary syndromes, coronary heart disease, coronary artery bypass
surgery, and peripheral artery disease); HTN, hypertension.
Cunha et al.BP¼ 1; ORhigh–normal BP¼ 1.7; ORGrade 1 BP¼ 3.1, and
ORGrade 2/3 BP¼ 9.4), HR above 75 bpm (OR¼ 1.7), and
diabetes (OR¼ 2.8).
Large artery damage
We also aimed to know how many individuals presented
PWV values over the established high-risk cutoff of 10m/s.
Figure 2 exhibits the age and sex-adjusted estimate of the
prevalence of individuals with measurements above
this value.
Men had a higher prevalence of high-risk arterial stiff-
ness both globally (X2¼ 32.4, P< 0.001) and particularly in
the age groups 30–39 (X2¼ 4.5, P< 0.05), 60–69 (X2¼ 8.9,
P< 0.01), and at least70 years (X2¼ 16.9, P< 0.001). Over-
all, a prevalence rate of 18.7% was observed in the popu-
lation (after adjustment for age and sex). Our attention was
drawn to the estimates obtained for the age classes below
50 years, where prevalence can reach as high as 14.1% (ages
40–49 years), with higher figures being recorded in men
(17.2%). The fact that 7.2% of men in the age class of 30–39
years exhibited large artery damage is a noticeable finding.
Logistic regression analysis models showed that age above
40 years and BP are variables increasing the risk of devel-
oping large artery damage; the logistic models for PWV
above 10m/s also evidence the difference between gen-
ders. Observing Figure SM1, http://links.lww.com/HJH/
A474, it becomes clear that for a 50% probability of devel-
oping PWV above 10, and for the same BP level, the
corresponding chronological age for males and females
differs approximately by 10 years (higher for men); for a
given age, the difference in probability of developing PWV
above 10, within the same BP class, is approximately 15%
(higher for men). HR is also a contributor, especially forTABLE 3. Linear regression models for pulse wave velocity as dependent variable, following logarithmic transformation
Variables
Males Females
Coefficients
(SE)
Standardized
coefficients
P
values
R2
incremental
Coefficients
(SE)
Standardized
coefficients
P
values
R2
incremental
Age 0.117 (0.007) 0.461 <0.001 0.411 0.113 (0.007) 0.474 <0.001 0.392
Age2 AQ90.034 (0.007) 0.109 <0.001 0.421 – – – –
SBP 0.059 (0.007) 0.216 <0.001 0.466 0.058 (0.007) 0.239 <0.001 0.425
HR 0.003 (0.001) 0.134 <0.001 0.485 0.003 (0.001) 0.123 <0.001 0.439
Fasting glucose 0.001 (0.0003) 0.069 0.005 0.492 – – – –
Constant 1.847 (0.039) – <0.001 – 1.904 (0.035) – <0.001 –
R2 0.492 0.439
xplanatory variables studied in the regression model: years of schooling, smoking, antihypertensive treatment, antidiabetic treatment, use of lipid-lowering drugs, prevalence of
stablished cardiovascular disease, mean fasting glucose, family history of premature cardiovascular disease, BMI, total cholesterol, high-density lipoprotein cholesterol, low-densityE
e
lipoprotein cholesterol, triglycerides, mean estimated glomerular filtration rate, and C-reactive p
4 www.jhypertension.comwomen (OR¼ 2.2), and diabetes status contributes to the
development of arterial stiffness in men (OR¼ 1.9) (Table
SM5, http://links.lww.com/HJH/A474).
Finally, putting side by side both the prevalence of
individuals that contributed PWV values above the median
and the expected 90th percentile (using the normal
‘healthy’ population as comparator) and the prevalence
of individuals with PWV above 10m/s (Fig. 3), we were
able to describe the coexistence of both early and late signs
of vascular aging in this population.DISCUSSION
We present for the first time in a population-based study in
Portugal, the mean values of PWV distributed by age
category and sex. The main finding is that PWV values
are markedly higher than expected from the European
reference values, especially in younger individuals and
males. We sought to describe how individuals’ PWV values
from a so-called low CVR area rank relative to European
references [16]. We confirmed a clear increase of PWV with
age, as well as higher mean levels of PWV in men, similar to
descriptions in other reports [27].
Only few studies have characterized the distribution of
PWV values using comprehensive population-based
samples. A recent publication from Uruguay [28] reports
population reference values higher than those published
here and in the ERVC, hinting (as previously suggested [27])
that ethnic and geographic differences could explain differ-
ent CVD geographic patterns. The Bogalusa Heart study
[29], the Enigma study [30], and the ARYA study [31]
reported mean PWV values for individuals below 40 years
that are lower than those found in the city of Guimara˜es/rotein. HR, heart rate; PWV, pulse wave velocity; SE, standard error.
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FIGURE 1 Prevalence of early vascular aging (EVA) stratified by age and showing
percentage of individuals above the 90th and 95th percentile of pulse wave
velocity (PWV) z-score values, using normal ‘healthy’ European individuals as com-
parators. These high values above expected percentiles in the population are
complementary explained by analyzing distribution histograms of PWV and PWV
z-scores as well as the difference in mean PWV values between the healthy Euro-
pean reference values collaboration population and the Guimara˜es/Vizela popu-
lation, presented in Supplementary Material – SM6 to SM8, http://links.lww.com/
HJH/A474. pc, percentile.
From arterial stiffness to early vascular agingVizela. Most of these studies were performed in either
healthy or lower CVRF populations (when compared with
our cohort).
Other population studies have been conducted in older
individuals [32,33], normotensives, and untreated hyper-
tensive patients [34], as well as a subset of 998 healthy
normotensive individuals in the Anglo-Cardiff Collabora-
tive Trial trial [35]. In this latter study, as well as in the2.3
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FIGURE 2 Percentage of individuals presenting carotid–femoral pulse wave
velocity value above the 10m/s high-risk cutoff, stratified by age and sex.
Journal of HypertensionBaltimore Longitudinal Study of Aging [36] and again in the
data we are presenting here, the existence of a nonlinear
progression of PWV with age is registered, evidencing a
much steeper increase from mid-life onward, more pro-
nounced in men.
Noticeably, in our (so-called) low-risk population, sig-
nificantly higher than expected PWV values are being
recorded: 80–84% of individuals under 50 years have a
PWV value above the expected median value for their age
class in the normal (‘healthy’) population of the ERVC
(Fig. 3) [16]. The male gender prevalence was expected,
and it also reflects either the higher prevalence of CVRF or
increased mean levels of several variables that are known to
influence PWV (mainly BP) in males (data not shown).
The independent predictive value of PWV concerning
cardiovascular events/mortality in population-based stud-
ies has been well established [37], and goes beyond the CVR
stratification achieved by use of well accepted risk scores
[38,39]. Therefore, when comparing the mean values of our
population with those of the normal ‘healthy’ population
[16], it is relevant to state that, compared with individuals
with no CVRF or established CVD, our individuals below
50 years present mean PWV values that are overall 1m/s
higher. Knowing that an increase in 1m/s in PWV is related
to an increase in cardiovascular events, cardiovascular
mortality, and overall mortality by 14, 15, and 15%, respect-
ively [15], our findings raise apprehension. We cannot
exclude that part of the difference between our population
and the ERVC could be attributed to methodological differ-
ences even if standardization and staff training took place
before screening. Still, recent evidence has emphasized
that c-fPWV improves CVR prediction and reclassifies indi-
viduals at risk for CVD events, especially concerning indi-
viduals below 61 years of age and particularly regarding
stroke [23].80
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FIGURE 3 Percentage of individuals above the median and above the 90th percen-
tile of the normal pulse wave velocity value expected for age, and above the
10m/s cutoff (stratified by age decade). pc, percentile.
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Cunha et al.The presented regression models allowed an expla-
nation of 44–49% of the recorded PWV values in our
population. Associations with age and SBP were not sur-
prising, as they have been extensively documented [40]. For
HR, the known strength of association is positive [33,40–42]
but weaker [40], a fact also reproduced here, with HR only
increasing significantly the risk of large artery damage in
women. The association of fasting glucose with PWV and
the increased risk of development of large artery damage
with diabetes were only observed for men, results that are
partially in line with data from the Framingham and the
Whitehall studies [33,42] but conflicting with the majority of
findings in the literature [40], a fact that cannot be disso-
ciated from the differences in prevalence of this condition
for both genders.
Early vascular aging
These results have a significant relevance for cardiovascular
prevention and raise several questions about not only the
CVR profile of our population but also concerning the need
for emergent clinical and public health measures. First, we
have shown that, whatever the method used to determine
its prevalence, there is an overwhelming higher prevalence
of EVA in younger age classes, especially below the age of
40. As expected, EVA has proven to be a useful concept to
identify individuals at risk in younger age classes where it
was more prevalent; the relative decline in EVA prevalence
after the age of 50 years accompanies the expected steeper
increase of PWV after that age, as has been shown in
different trials [35]. This could mean that differences accord-
ing to EVA prevalence will become more visible in younger
age groups, reflecting differential biological aging of the
arterial tree, but that convergence applies to older age
groups when the impact of chronological aging in general
overrides the differential biological aging, more visible in
younger individuals. This is in line with epidemiological
findings that PWV is a relatively stronger cardiovascular risk
marker in middle-aged individuals than in the elderly [23].
The other complementary explanation is survival bias, a
phenomenon related to selective better survival in individ-
uals with low PWV.
We observed that males were particularly afflicted by
EVA across all age classes, a fact that cannot be dissociated
from the overall higher CVRF levels/prevalence in males.
Estimation of EVA prevalence is difficult in the absence of
consensus on its definition. In addition, the analysis is not
focused in outliers in a distribution, but rather with a global
shift of the distribution of real values compared with
predicted values. It is more conservative to say that the
real EVA prevalence should lie within the values deter-
mined by both definitions used here (>97.5th percentile of
normal mean PWV values stratified by age or >2SD of the
mean PWV adjusted to BP class – see Supplemental
Materials, http://links.lww.com/HJH/A474). This would
provide a global prevalence of EVA between 8.7 and
12.5%, and the following prevalence rate intervals could
be determined for every age class: 20.1–26.2% (<30 years),
10.0–12.8% (30–39 years), 7.2–14.9% (40–49 years),
2–5.7% (50–59 years), 1.6–2.6% (60–69 years), and
1.1–3.2% (70 years). In addition, we found that 40.2%6 www.jhypertension.comof individuals in the age class below 30 years and 26.4–
29.3% of individuals in the age classes 40–49 and 30–39
years, respectively, are above the 90th percentile of PWV
z-score. This impressive result means that even if not strictly
considered as EVA individuals, over 34.7% of individuals
below 40 years are above the 90th percentile of PWV
expected for their age: these individuals also have signifi-
cant added risk for the development of CVD (pointing out
the fact that their mean PWV value is at least 1m/s above
their normal/reference counterparts [15,16]). They deserve
a particularly strict follow-up, as proposed elsewhere [12].
HR appears as one of the variables associated with EVA.
The frequency of individuals exhibiting HR above 75 bpm is
slightly higher across all age groups, in particular in the
30–39 years group. Looking at Table SM3, http://links.
lww.com/HJH/A474, the absolute difference in HR
between EVA and non-EVA individuals is rather small
(2 bpm in the whole population, 3.1 and 3.6 bpm in the
age groups 30–39 and 40–49 years, respectively). This
raises the question of the real biological explanation of
this statistical finding, for example, a relatively increased
activity of the sympathetic nervous system. On the other
hand, could specific genetic alterations [9] associated with
early, prolonged ‘environmental’ stressors (mediated
through sympathetic nervous system) result in stiffer than
average arteries? The significance of HR as a determinant of
EVA may support this hypothesis.
To explain this increased EVA prevalence in our popu-
lation, one cannot forget the importance of increased
average BP and pulse pressure. Individuals with EVA have
significantly higher SBP (Table SM3, http://links.lww.com/
HJH/A474), way above the minimum exposure risk for the
development of CVD.
Other authors have proposed a role of stress hormones
acting on the endothelium as well as media smooth muscle
layer for contraction, suggesting that PWV increases not
only as a reflection of arterial wall structure modification
(elastin degeneration, collagen material increase) [6,17] but
also with increased vascular smooth muscular cell tonus
[43]. At this point, we cannot offer an explanation for the
influence on these results of early-life determinants or other
proposed contributors to accelerated vascular aging as
(short-term) BP variability [44] or salt consumption (recent
studies in Portugal have reported the average individual salt
consumption as reaching 10.7 g/day in adults, and 7.8 g/day
in 10–12-year-old children [45,46]).
Large artery damage (pulse wave velocity
above 10m/s)
The observation that 18.7% of our population (mean age of
47 years) displays large artery damage is novel and surpris-
ing. In Copenhagen [39], Framingham [38], and Vobarno
[47], significantly older aged populations registered the
prevalence of large artery damage between 23.6 and
31.7%. In our population, for the age class 60–70 years,
42% of the individuals would have large artery damage. We
have not seen data including the prevalence of increased
PWV in the adult population stratified by age class and sex
presented elsewhere. Still, values observed in younger age
classes are striking. Logistic regression models concerningVolume 33  Number 1  Month 2015
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AQ7
From arterial stiffness to early vascular agingPWV above 10m/s have been discussed previously, mainly
obviating the role of age and BP in the development of large
artery damage, with differences between genders observed
only in the magnitude of risk increase.
Strengths and limitations
The strength of our approach resides on having set up an
evaluation of an homogenous population living in adjacent
cities in the same region of northern Portugal and using a
very large random sample representative of all adult age
classes, levels of education, and professional status. The
study also has clear limitations. Only one measurement of
PWV was performed per individual. A white coat effect
cannot be excluded, particularly in younger individuals.
The precise definition of EVA is questionable in the absence
of a general definition. PWV might not be sufficient for
characterizing EVA, and it could also include other cardi-
ovascular or age-related target organ damage variables [48].
We also used the reference value data to characterize EVA.
This set of data is valuable, but not immune to bias as it was
collected over a variety of locations, using various tech-
niques, and included individuals defined as healthy or
bearing risk factors on a post-hoc basis; on another
perspective, we cannot exclude that a historic cohort effect
could have some influence in our results, when we com-
pare our data with the data from the ERVC (that included
cohorts analyzed over 20 years ago).
CONCLUSION
Consistently, whether looking at mean absolute PWV val-
ues, prevalence of EVA based on distribution (>97.5 per-
centile or >2SD over mean for age categories) or
prevalence of large artery damage (PWV > 10m/s), we
observed a pattern of increased signs of arterial damage,
portraying a cardiovascular risk picture different from what
could be expected in a low cardiovascular risk country as
Portugal. As Portugal has paradoxically one of the highest
rates of stroke in Europe, finding that the general popu-
lation has skewed distribution of PWV with much higher
values might be particularly meaningful when recent evi-
dence shows that c-fPWV improves CVR prediction, especi-
ally for stroke [23]. At the same time, the fact that c-fPWV has
a higher predictive value in younger ages suggests that we
cannot disconnect the high prevalence of EVA from large
artery damage in young ages, and stroke (or other CVD) at
older age. Only the longitudinal follow-up of this cohort
will provide answers to these questions.
The high prevalence of EVA together with the impressive
percentage (34.7%) of individuals below 40 years who are
above the 90th percentile of the expected PWV value for
their age and BP class is clearly worrisome, increasing also
the need for better knowledge of prevalence and early
control of CVRF as well as tighter risk stratification and
inherent clinical intervention.
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Reviewer 1
This paper is focused on the study of the north Portuguese
population with a known high prevalence of HTN and
stroke. The author studied pulse wave velocity (PWV) in
3038 subjects. The results show that in this population PWV
values were higher than expected. Strengths of this work
are certainly the large population evaluated, the state of the
art method and the correct methodologic approach, includ-
ing the statistical analysis. A weakness is the absence of
other important clinical parameters, which would have
helped in mechanistic explanations.
Reviewer 2
The authors assessed early vascular aging (EVA) by measur-
ing pulse wave velocity (PWV) in subjects aged 18–96years. They compared themeasured PWV values with those
published in the European Reference Values Project (RVP).
They considered a subject to be at risk for EVA when the
PWV value exceeded the 97.5th percentile of the value
found in the subgroup of RVP called ‘healthy subjects’.
The values were stratified according to age decades. The
overall prevalence of EVA was 12.5%, the highest preva-
lence being in the youngest subjects aged below 30 years;
on the contrary, when the absolute cut-off value of PWV
>10m/s was taken, the prevalence of pathologic values
increased steeply with age.
Studying the relative increase of PWV, i.e. comparing the
measured value with the reference value at the same age
(and blood pressure) group, seems a sound approach to
discover arterial pathological changes at a young age.
This may be a good approach for early prevention in
the future.Volume 33  Number 1  Month 2015
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